860549P

C24:1 Glucosyl(β) Ceramide (d18:1/24:1(15Z))

Avanti Research^™ - A Croda Brand 860549P, powder

• Sinonimo/i: D-glucosyl-β-1,1′-N-nervonoyl-D-erythro-sphingosine
• Formula empirica (notazione di Hill): C₄₈H₉₁NO₈
• Numero CAS: 887907-50-8
• Peso molecolare: 810.24
• Codice UNSPSC: 12352211
• NACRES: NA.25

Proprietà

• Forma fisica: powder
• Confezionamento: pkg of 1 × 5 mg (860549P-5mg)
• Produttore/marchio commerciale: Avanti Research^™ - A Croda Brand 860549P
• Tipo di lipide: sphingolipids
• Condizioni di spedizione: dry ice
• Temperatura di conservazione: −20°C
• Stringa SMILE: [H][C@](/C=C/CCCCCCCCCCCCC)(O)[C@@]([H])(NC(CCCCCCCCCCCCC/C=C\CCCCCCCC)=O)CO[C@H](O1)[C@H](O)[C@@H](O)[C@@H]([C@H]1CO)O

Descrizione

Descrizione generale

β-Glucosylceramides or glucocerebrosides (GlcCers) are synthesized from the glycosphingolipids by β-GlcCer synthase. They are synthesized in Golgi and endoplasmic reticulum and localized in the cytosolic side of cell membrane. GlcCers are omnipresent.

Applicazioni

C24:1 Glucosyl(β) Ceramide (d18:1/24:1(15Z)) may be used:

• as a standard hexosylceramide for hydrophilic interaction chromatography-based liquid chromatography mass spectroscopy
• to test its nuclear factor of activated T-cells (NFAT) activation
• in human natural killer T (NKT) cell potency assays

Azioni biochim/fisiol

β-Glucosylceramides (β-GlcCer) levels are elevated inlevels in Gaucher′s disease, due to the deficiency of β-glucosidase. β-GlcCer participates in the inflammatory and acquired immune responses by binding mincle on myeloid cells and has immunostimulatory activity.

Confezionamento

5 mL Amber Glass Screw Cap Vial (860549P-5mg)

Note legali

Avanti Research is a trademark of Avanti Polar Lipids, LLC

Informazioni sulla sicurezza

• Codice della classe di stoccaggio: 11 - Combustible Solids